|
Honorary Chairman Seo Jeong-jin has officially retired. Honorary Chairman Seo said at the 30th regular shareholders’ meeting held at Incheon Songdo Convensia on the 26th, saying, “This company is not my private company, but a shareholder company and an employee company.” I kept the story.” While honorary chairman Seo stepped down from the management front at the end of last year, he officially put down his position as an executive director on this day.
His sons filled the position of the executive director he left. Celltrion passed the agenda to elect Celltrion Senior Vice President Seo Jin-seok, the eldest son of the honorary chairman, as the executive director of Celltrion and Celltrion at the shareholders’ meeting on the same day. Also, through the shareholders’ meeting, the second son, Director of Celltrion Seo Jun-seok, was appointed as the executive director.
Senior Vice President Seo was born in 1984. After completing his doctoral course at KAIST, he served as the Director of the Celltrion Research and Development (R&D) Headquarters, Director of the Biotechnology 1 Research Institute, and the CEO of Celltrion Skincure. Currently, he is in charge of Celltrion Product Development Division. Director Seo was born in 1987, worked at the Celltrion Product Development Headquarters and Management Support Office, and is currently working as the head of operation support in the manufacturing sector. Senior Vice President Seo and Director Seo are in office for three years.
Senior Vice President Seo, the eldest son, is expected to take over as Chairman of the Celltrion Board of Directors on behalf of the Honorary Chairman. Honorary Chairman Seo said, “Management is centered on the representative directors who are professional managers, and the chairman of the board of directors is responsible for reviewing the matters that need to be approved under the commercial law and reviewing the approval. Even if you don’t know, it is a policy to do our best to create a similar answer.”
Regarding the group’s blueprint, he said, “Last year, we ranked 35th out of 300,000 pharmaceutical companies worldwide (based on operating profit). We aim to go to the 25th place this year, and we plan to go to the top 10 by 2030 in no time. There is” he said. He added, “We have made a grand plan to increase operating profit of 2 trillion won (total of three listed companies such as Celltrion, Celltrion Healthcare, and Celltrion Pharmaceutical) through existing products, excluding corona antibody treatment drugs.”
Chairman Seo said, “Because Celltrion Group is not highly dependent on individuals, don’t be afraid that if I fall out, don’t be afraid and understand it as a natural accompanying procedure.”